RAFAEL HOLDINGS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
RAFAEL HOLDINGS, INC. (RFL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of -$341.00 thousand for the 3-month period ending 2022-04-30, per its 10-Q filed 2022-06-14.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2022-06-14
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-04-30 was -$341.00K, a 146.21% decline year-over-year.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-01-31 was -$454.00K, a 118.24% decline year-over-year.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2021-10-31 was $211.00K, a 77.65% decline year-over-year.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2021-07-31 was $587.00K, a 68.99% decline year-over-year.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2021 was $4.76M, a 99.50% increase from fiscal 2020.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2020 was $2.38M, a 162.95% increase from fiscal 2019.
- RAFAEL HOLDINGS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2019 was $907.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2022-04-30 | -$341.00K 10-Q · filed 2022-06-14 | -$795.00K derived: sum of 2 quarters · filed 2022-06-14 | -$584.00K 10-Q · filed 2022-06-14 | $3.00K derived: sum of 4 quarters · filed 2022-06-14 |
| 2022-01-31 | -$454.00K 10-Q · filed 2022-03-17 | -$243.00K 10-Q · filed 2022-03-17 | $344.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.08M derived: sum of 4 quarters · filed 2022-06-14 |
| 2021-10-31 | $211.00K 10-Q/A · filed 2022-02-28 | $798.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.54M derived: sum of 3 quarters · filed 2022-06-14 | $4.03M derived: sum of 4 quarters · filed 2022-06-14 |
| 2021-07-31 | $587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | $1.32M derived: sum of 2 quarters · filed 2022-06-14 | $3.81M derived: sum of 3 quarters · filed 2022-06-14 | $4.76M 10-K · filed 2021-10-18 |
| 2021-04-30 | $738.00K 10-Q · filed 2022-06-14 | $3.23M derived: sum of 2 quarters · filed 2022-06-14 | $4.17M 10-Q · filed 2022-06-14 | $6.06M derived: sum of 4 quarters · filed 2022-06-14 |
| 2021-01-31 | $2.49M 10-Q · filed 2022-03-17 | $3.43M 10-Q · filed 2022-03-17 | $5.33M derived: sum of 3 quarters · filed 2022-03-17 | $5.30M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-10-31 | $944.00K 10-Q/A · filed 2022-02-28 | $2.84M derived: sum of 2 quarters · filed 2022-02-28 | $2.81M derived: sum of 3 quarters · filed 2022-02-28 | $3.37M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-07-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | $1.86M derived: sum of 2 quarters · filed 2021-10-18 | $2.42M derived: sum of 3 quarters · filed 2021-10-18 | $2.38M 10-K · filed 2021-10-18 |
| 2020-04-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | $529.00K derived: sum of 2 quarters · filed 2021-06-14 | $492.00K 10-Q · filed 2021-06-14 | $985.00K derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-01-31 | $557.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-17 | $520.00K 10-Q · filed 2021-03-17 | $1.01M derived: sum of 3 quarters · filed 2021-03-17 | |
| 2019-10-31 | -$37.00K 10-Q · filed 2020-12-15 | $456.00K derived: sum of 2 quarters · filed 2020-12-15 | ||
| 2019-07-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | $907.00K 10-K · filed 2020-10-29 | ||
| 2019-04-30 | $414.00K 10-Q · filed 2020-06-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |